Vygon UK is the exclusive distributor of the SecurAcath in England, Scotland and Wales

Vygon UK now provides complete sales, marketing and clinical support for the market leading SecurAcath device.

Vascular Access Device Securement – State of the Art

WoCoVA Meet the Experts webinar recording.  Watch three excellent presentations on the latest in VAD securement followed by Q&A.

Subcutaneous anchorage of PICCs – Fabrizio Brescia

Vascular Access Device (VAD) Securement in Neonates and Children – Amanda Ullman

Current Options for VAD Securement – Evan Alexandrou

SecurAcath® had Lowest Incidence of Migration and Dislodgement

Jon Bell and Dr. Mickey Hawes discuss the results of the Systematic Review of the Safety and Efficacy of Central Vascular Access Device Securement.

SecurAcath® Awarded Innovative Technology Contract from Vizient

Vizient is the largest member-driven health care performance improvement company in the U.S.  The contract was based on the recommendation of SecurAcath by hospital experts who serve on one of Vizient’s member-led councils that identify technologies that have the potential to enhance clinical care, patient safety, health care worker safety or improve business operations of health care organizations.  Vizient currently serves more than 50% of the nation’s acute care providers and 95% of the nation’s academic medical centers.

Eloquest Healthcare is now the SecurAcath U.S. sales partner.

Together, the companies will provide hospitals and clinicians with the proven benefits of the SecurAcath to improve outcomes and reduce total medical expenses.

How Does the SecurAcath Work?

Brief SecurAcath Demonstration Video

Catheter Securement Choice Does Affect Central Line-Associated Bloodstream Infection Risk

SecurAcath Significantly Reduces CLABSI Risk

Recent study in AJIC* showed an adhesive catheter securement device had a 288% increase in risk of CLABSI compared to the SecurAcath.

CLABSIs yield tremendous negative consequences affecting patients and health care facilities globally. The CDC estimates the annual cost of CLABSI is more than $1 billion, the cost per patient is more than $16,000.

SecurAcath offers significant cost savings due to reduced catheter complications

SecurAcath is Recommended by the National Institute for Care Excellence